We are live on ! Find out more
SKYE icon

Skye Bioscience
SKYE

39 hedge funds and large institutions have $9.91M invested in Skye Bioscience in 2026 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 8

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2% less ownership

Funds ownership: 50.32% → 48.32% (-2%)

18% less capital invested

Capital invested by funds: $12.1M → $9.91M (-$2.18M)

22% less funds holding

Funds holding: 50 → 39 (-11)

36% less call options, than puts

Call options by funds: $25K | Put options by funds: $39K

64% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 14

Holders
39
Holders Change
-11
Holders Change %
-22%
% of All Funds
0.48%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
5
Increased
9
Reduced
8
Closed
14
Calls
$25K
Puts
$39K
Net Calls
-$14K
Net Calls Change
-$53K

Top Buyers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
+$163K
2
BBA
Baker Bros. Advisors
New York
+$102K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$54.7K
4
UBS Group
UBS Group
Switzerland
+$26.5K
5
BlackRock
BlackRock
New York
+$3.5K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$99.6K
2
SSA
Schonfeld Strategic Advisors
New York
-$70K
3
Two Sigma Investments
Two Sigma Investments
New York
-$21.2K
4
HF
HRT Financial
New York
-$20K
5
Jane Street
Jane Street
New York
-$18.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
5VM
1
5AM Venture Management
California
$5.95M – – –
VVM
2
Versant Venture Management
California
$1.23M – – –
BBA
3
Baker Bros. Advisors
New York
$968K +$102K +124,605 +9%
VCM
4
Vanguard Capital Management
Pennsylvania
$470K +$623K +764,457 New
SFM
5
Sphera Funds Management
Israel
$417K +$163K +200,000 +42%
BlackRock
6
BlackRock
New York
$176K +$3.5K +4,290 +2%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$170K +$54.7K +67,105 +32%
Millennium Management
8
Millennium Management
New York
$159K -$99.6K -122,278 -32%
PIM
9
Platinum Investment Management
Australia
$143K – – –
VFT
10
Vanguard Fiduciary Trust
Pennsylvania
$64.1K +$84.9K +104,229 New
State Street
11
State Street
Massachusetts
$46.3K – – –
UBS Group
12
UBS Group
Switzerland
$28.1K +$26.5K +32,476 +244%
XT
13
XTX Topco
Cayman Islands
$25.1K -$9.88K -12,121 -23%
Two Sigma Investments
14
Two Sigma Investments
New York
$15.8K -$21.2K -26,022 -50%
EGM
15
Engineers Gate Manager
New York
$12.4K -$2.4K -2,944 -13%
Northern Trust
16
Northern Trust
Illinois
$12.4K – – –
Barclays
17
Barclays
United Kingdom
$11.1K -$2.58K -3,162 -15%
Group One Trading
18
Group One Trading
Illinois
$4.43K -$8.55K -10,492 -59%
VGA
19
Vanguard Global Advisers
Pennsylvania
$2.8K +$3.71K +4,557 New
Morgan Stanley
20
Morgan Stanley
New York
$1.57K -$1.4K -1,720 -40%
Federated Hermes
21
Federated Hermes
Pennsylvania
$712 – – –
Osaic Holdings
22
Osaic Holdings
Arizona
$364 +$487 +598 +29,900%
National Bank of Canada
23
National Bank of Canada
Quebec, Canada
$242 – – –
TWC
24
TD Waterhouse Canada
Ontario, Canada
$51 +$44 +54 +216%
JP Morgan Chase
25
JP Morgan Chase
New York
$39 – – –
1
2 3

SKYE Hedge Fund Activity: Q1 2026 in Review

39 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Skye Bioscience (SKYE) for Q1 2026, worth a combined $9.91M — down 18% from $12.1M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of SKYE and 5 opened new positions — a net loss of 9 holders — while 8 trimmed existing stakes and 9 added.

The largest buyer was Sphera Funds Management, adding an estimated $163K. The largest seller was Millennium Management, cutting an estimated $99.6K.

  • 39 institutional investors held Skye Bioscience (SKYE) as of Q1 2026, down from 50 in Q4 2025.
  • Funds reported $9.91M of Skye Bioscience stock for Q1 2026, down 18% quarter-over-quarter.
  • 5 funds opened new Skye Bioscience positions in Q1 2026 and 14 closed out, a net change of -9 holders.
  • The largest Skye Bioscience buyer in Q1 2026 was Sphera Funds Management, an estimated $163K added.
  • The largest Skye Bioscience seller in Q1 2026 was Millennium Management, an estimated $99.6K sold.

Based on aggregated 13F filings for Q1 2026.